Literature DB >> 7509146

Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro.

K Morikawa1, F Oseko, S Morikawa, M Sawada.   

Abstract

Recent investigations have shown that some antibiotics also work as immunomodulators. We have recently reported that fosfomycin (FOM) has an immunomodulatory effect on human B-cell activation. FOM is a unique antibiotic which is chemically unrelated to any other known antibacterial agent. In the present study, we examined the effect of FOM on human T-cell function. FOM inhibited the proliferation of human lymphocytes induced by polyclonal T-cell mitogens in a dose-dependent manner. FOM also strongly suppressed mixed lymphocyte reaction and interleukin-2 (IL-2) production by T cells. Moreover, FOM inhibited the expressions of IL-2 receptor (CD25) and transferrin receptor (CD71) on the activated T-cell surfaces. These data suggest that FOM may block the T-cell division during the transition from G1 to S phase of the cell cycle. Combined treatment with FOM and low-dose cyclosporin A or FK506 caused additive or synergistic suppression of T-cell proliferation, but not on IL-2 receptor expression. It seems that the mode of action of FOM on T-cell function involves a specific suppression of IL-2 production.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509146      PMCID: PMC192778          DOI: 10.1128/AAC.37.12.2684

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process.

Authors:  E L Larsson
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

Review 2.  Allograft response in vitro.

Authors:  P Häyry; L C Andersson; S Nordling; M Virolainen
Journal:  Transplant Rev       Date:  1972

Review 3.  FK-506--how much potential?

Authors:  A W Thomson
Journal:  Immunol Today       Date:  1989-01

4.  Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages.

Authors:  K Takeshita; I Yamagishi; M Harada; S Otomo; T Nakagawa; Y Mizushima
Journal:  Drugs Exp Clin Res       Date:  1989

5.  Immunomodulatory effect of fosfomycin on human B-lymphocyte function.

Authors:  K Morikawa; F Oseko; S Morikawa
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

6.  Regulation of lymphocyte blastogenesis and antibody production by soluble factor released by a human B-lymphoblastoid cell line.

Authors:  K Morikawa; S Morikawa; K Imai; F Oseko
Journal:  Cytokine       Date:  1991-11       Impact factor: 3.861

7.  Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines.

Authors:  A W Thomson; D K Moon; C L Geczy; D S Nelson
Journal:  Immunology       Date:  1983-02       Impact factor: 7.397

8.  Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2.

Authors:  L M Neckers; J Cossman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  The mechanism of action of fosfomycin (phosphonomycin).

Authors:  F M Kahan; J S Kahan; P J Cassidy; H Kropp
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

  10 in total
  9 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Modulatory effect of antibiotics on cytokine production by human monocytes in vitro.

Authors:  K Morikawa; H Watabe; M Araake; S Morikawa
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Fosfomycin reduces CD15s-related antigen expression of Streptococcus pyogenes.

Authors:  K Hirota; K Murakami; K Nemoto; T Ono; T Matsuo; H Kumon; Y Miyake
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

5.  Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro.

Authors:  K Morikawa; F Oseko; S Morikawa; K Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 7.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 8.  Fosfomycin: Uses and potentialities in veterinary medicine.

Authors:  D S Pérez; M O Tapia; A L Soraci
Journal:  Open Vet J       Date:  2014-03-16

9.  Fosfomycin suppresses RS-virus-induced Streptococcus pneumoniae and Haemophilus influenzae adhesion to respiratory epithelial cells via the platelet-activating factor receptor.

Authors:  Shin-ichi Yokota; Tamaki Okabayashi; Yuko Yoto; Tsukasa Hori; Hiroyuki Tsutsumi; Nobuhiro Fujii
Journal:  FEMS Microbiol Lett       Date:  2010-06-28       Impact factor: 2.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.